Nanotechnology Now - Press Release: Early Detection for Alzheimer's, Chronic Fatigue Syndrome and Other Diseases

Home > Press > Early Detection for Alzheimer's, Chronic Fatigue Syndrome and Other Diseases

Abstract:
In Vitro Diagnostic Tests from Neuro-Biotech Corp. to a Doctor Near You!

Early Detection for Alzheimer's, Chronic Fatigue Syndrome and Other Diseases

Basel, Switzerland | Posted on September 20th, 2010

Neuro-Biotech Corporation (PINKSHEETS: MRES)(OTCQB: MRES) is a worldwide biotechnological enterprise involved in the unique international niche of clinical neuroscience diagnostic testing. Neuro-Biotech Corp. uses proprietary molecular nanotechnology IVDDs (in vitro diagnostic devices) for the quantitative measurement of blood parameters to evaluate the input and output of the brain through specific neuro-biomarkers. As a result of more than 20 years of R&D, Neuro-Biotech Corp.'s specific expertise in clinical neurosciences applied enzymology is dedicated to the understanding of the relationship between the neurotransmitter families within the brain and their various influences on the peripheral systems involving the Hypothalamo-Pituitary Adreno-Sympathetic (HPAS) Axis. The HPAS Axis manages body mechanisms against stressful situations in order to maintain the homeostasis responsible for the resistance of the organism to its psycho-socio-environment through psycho-neuro-immune and endocrine systems.

This unique understanding of the communication between the brain and the human body, has led to the development of in vitro diagnostic blood tests. They are used for the detection, prevention, monitoring and follow-up of the major stress-related, socio-professional and occupational diseases, such as Chronic Fatigue Syndrome (CFS), Great Anxiety (GA), Panic Syndrome (PS), Neuropathies or Fibromyalgia (FM), Cardiovascular diseases like Essential Hypertension or Arrhythmia, Neurodegenerative diseases such as Alzheimer and Parkinson Diseases as well as Mental-Health Disorders in the vein of Depression and Schizophrenia.

Neuro-Biotech Corp's goals have resulted in a new and reliable portfolio of quantitative blood tests that provide general practitioners and specialists useful clinical parameters for the diagnosis of neuroscience-related diseases or physio-pathological impairments. This is accomplished by identifying abnormal readings of specific bio-markers within the blood or other biological fluids. Neuro-Biotech Corp's diagnostic tests are without equal in being non-invasive, sensitive, reliable and rapidly done as an essential complement to current clinical laboratory testing procedures.

Neuro-Biotech presently has the opportunity to commercialize 12 clinical Neuro Blood Tests through partnerships, as specialized blood testing for a progressive clinical neuroscience investigation of targeted diseases, thus selectively monitoring specific neuro-biomarkers related to the neuro-immune and endocrine systems. Caregivers will now be able to evaluate and establish an individual's ability to react to stress and, to identify the appropriate neuro-endocrine and immune dysfunctioning. By monitoring bio-indicators related to workplace stress-related diseases and mental-health disorders, efficient patient treatment and follow-up are feasible.

Forward Looking Statements

This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

####

For more information, please click here

Contacts:

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: